Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Andrew R. Pachner
Sign up to set email alerts
235
Publications
5,203
Citation Statements Received
4,349
Citation Statements Given
How they've been cited
8,057
176
5,013
14
How they cite others
6,631
244
4,093
12
Affiliations
Rutgers New Jersey Medical School
,
Dartmouth–Hitchcock Medical Center
Publications
Order By: Most citations
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos
1
,
Bar-Or
2
,
Cree
3
et al.
2018
The Lancet
974
10
772
2
2
Get article
Add to collection
Cite
The neurotropic herpes viruses: herpes simplex and varicella-zoster
Steiner
1
,
Kennedy
2
,
Pachner
3
2007
The Lancet Neurology
578
12
471
1
Get article
Add to collection
Cite
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Bar‐Or
1
,
Pachner
2
,
Menguy-Vacheron
3
et al.
2014
Drugs
Abstract
Show
381
2
257
0
Get article
Add to collection
Cite
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Ho
1
,
Campbell
2
,
Chang
3
et al.
2018
The Lancet Neurology
Abstract
Show
350
4
243
1
Get article
Add to collection
Cite
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
Polman
1
,
Bertolotto
2
,
Deisenhammer
3
et al.
2010
The Lancet Neurology
200
2
173
0
Get article
Add to collection
Cite
Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study
Cadavid
1
,
Wolansky
2
,
Skurnick
3
et al.
2009
Neurology
Abstract
Show
182
4
164
0
Get article
Add to collection
Cite
The triad of neurologic manifestations of Lyme disease
Pachner
1
,
Steere
2
1985
Neurology
Abstract
Show
571
4
161
0
Get article
Add to collection
Cite
Lyme neuroborreliosis: infection, immunity, and inflammation
Pachner
1
,
Steiner
2
2007
The Lancet Neurology
172
3
119
0
Get article
Add to collection
Cite
1
2
3
4
5